Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

User seeks Procyanidin B2 supplement source and asks for dosage comparison. Another user requests study details and apple type importance.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

A user's 7-month progress using 1 mg finasteride and topical minoxidil, with no side effects from the finasteride, achieving baby hairs on the hairline and other positive results. Other users have discussed different treatments such as microneedling and supplements, providing advice and encouragement to the poster.

The conversation discusses managing seborrheic dermatitis (sebderm) and male pattern baldness (MPB) with treatments like finasteride, coal tar shampoo, Nizoral, and oral minoxidil. Users suggest dietary changes, regular shampooing, and using antifungal products to control sebderm before considering minoxidil.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

The conversation is about a user's progress in treating hair loss using 1mg finasteride, topical minoxidil once at night, and weekly 1.5mm microneedling. The user reports significant improvement and no side effects, while others discuss their experiences and offer advice on similar treatments.

A user is experimenting with a homemade solution of WAY-316606 for hair regrowth, combining it with other treatments like minoxidil and dutasteride. The community expresses concern over the safety and mental health implications of such drastic measures, with mixed opinions on the effectiveness of WAY-316606.

The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.

A 49-year-old is documenting their hair regrowth journey using tretinoin cream, minoxidil foam, and finasteride. They report thicker hair and improved confidence, though progress feels slow and mentally challenging.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The user is using finasteride, RU58841, and various natural supplements and treatments like seamoss, fish oil, and black rice water spray to combat hair loss, avoiding minoxidil due to dependency concerns. They report thicker hair and regained confidence, while discussing the potential risks and benefits of RU58841 with others.

The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.

The user has been using finasteride and minoxidil for 7 months, seeing thicker hair but no temple regrowth, and is considering switching to dutasteride. Another person suggested trying microneedling on the temples before changing medications.

A 30-year-old shared their 7-month hair regrowth progress using topical minoxidil twice daily, 1 mg finasteride daily, and weekly microneedling. Users discussed the effectiveness of these treatments and suggested adding retinol for better results.